-
2023-509923-42-00
4
2017-07-06
HER2- positive breast cancer
-
2024-510704-37-00
5
2017-03-22
ER+/HER2- metastatic breast cancer
-
2024-511722-31-00
9
2016-11-29
Acute Myeloid Leukemia (AML)
-
2024-515460-31-00
4
2016-11-07
CHRONIC PHASE CHRONIC MYELOGENOUS LEUKAEMIA
-
2022-501253-37-00
4
2016-02-02
(A) Anal Squamous Cell Carcinoma,
(B) Biliary Adenocarcinoma (gallblad
-
2024-513509-30-00
5
2016-01-11
Progressive or recurrent germ cell tumor (measurable or non-measurable
-
2024-513976-16-00
5
2015-06-26
squamous cell carcinomas of the larynx or hypopharynx locally advance
-
2024-514904-14-00
4
2014-10-08
Patients with metastatic or unresectable locally advanced malignancies
-
2024-516996-34-00
5
2012-04-12
oestrogen-receptor (ER)-positive HER2-negative breast carcinoma
-
2024-514844-10-00
4
2010-03-18
Retinoblastoma
-
2024-514756-32-00
5
2007-03-19
High grade osteosarcoma
-
2023-509322-22-00
4
2025-11-26
localized colon cancer
-
2024-515903-21-00
3
2025-10-31
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
-
2024-519278-37-00
4
2025-10-22
Lupus Nephritis
-
2024-517254-99-00
4
2025-09-16
The patients enrolled in IMMUNORARE will be adult patients with 5 rar
-
2023-510559-41-00
4
2025-01-02
Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
-
2023-505840-20-00
9
2024-08-16
B-Cell Acute Lymphoblastic Leukaemia
-
2023-507220-23-00
5
2024-07-26
Transthyretin Amyloidosis with Cardiomyopathy
-
2024-512626-28-00
5
2024-03-28
Duchenne Muscular Dystrophy
-
2024-518003-22-00
4
2023-01-20
Complicated urinary tract infections including acute pyelonephritis
-
2023-506136-32-00
9
2020-10-12
Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leukemia (
-
2023-508766-14-00
10
Sickle Cell Disease
-
2025-521480-12-00
1
2025-10-22
Advanced solid tumors, Breast Cancer
-
2024-518797-13-00
3
2025-07-10
systemic lupus erythematosus [SLE]/lupus nephritis [LN], idiopathic in